Medication nonadherence
nonadherence
REGRESSION
At baseline, among the NA patient cases, providers identified NA in their patients only 2.0% of the time, with no difference between study arms (p = 0.414) (Table 
Primary Variant Diagnosis and Related Treatment, by Case VariantThe improvement in NA case diagnosis in intervention 1 led to improved clinical care manifested by continuing medication and discussing the importance of medication adherence. After introduction of the CDM test, intervention continued the nonadherence medications by an additional 20.8% (p = 0.003) (Table Regression modeling confirmed that intervention were 50.4x more likely to identify NA (95% C.I. 2.9-871.2) and 3.3x more likely to continue the medications for which their patients were nonadherent, although the latter proved not to be significant (O.R. 0.6–19.3).